Claus Bachert Selected Research

desloratadine (Aerius)

1/2012	Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review.
11/2011	Efficacy of second-generation antihistamines in patients with allergic rhinitis and comorbid asthma.
1/2010	Efficacy of desloratadine in persistent allergic rhinitis - a GA²LEN study.
1/2010	Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.
5/2009	A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis.
9/2007	Desloratadine treatment for intermittent and persistent allergic rhinitis: a review.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Claus Bachert Research Topics

Disease

100	Nasal Polyps (Nasal Polyp) 11/2022 - 11/2003
94	Rhinosinusitis 11/2022 - 09/2003
84	Asthma (Bronchial Asthma) 01/2022 - 05/2003
67	Inflammation (Inflammations) 11/2022 - 11/2002
42	Allergic Rhinitis 01/2022 - 09/2002
31	Hypersensitivity (Allergy) 10/2021 - 06/2005
28	Polyps 01/2022 - 11/2003
13	Rhinitis 12/2020 - 10/2004
12	Seasonal Allergic Rhinitis (Hay Fever) 01/2018 - 04/2003
10	Infections 01/2022 - 01/2011
7	Atopic Dermatitis (Atopic Eczema) 01/2022 - 05/2002
6	Eosinophilia 11/2022 - 01/2013
6	Nasal Obstruction 01/2022 - 05/2009
6	Rhinorrhea 01/2020 - 10/2004
5	Pruritus (Itching) 01/2022 - 10/2004
5	COVID-19 01/2021 - 05/2020
5	Neoplasms (Cancer) 01/2021 - 11/2017
5	Allergic Fungal Sinusitis 12/2015 - 11/2006
5	Cystic Fibrosis (Mucoviscidosis) 01/2015 - 10/2009
5	Edema (Dropsy) 01/2013 - 05/2009
4	Eczema 01/2022 - 04/2007
4	Chronic Obstructive Pulmonary Disease (COPD) 10/2020 - 09/2004
4	Sneezing 11/2018 - 10/2004
4	Perennial Allergic Rhinitis 04/2015 - 09/2002
3	Anosmia 01/2022 - 03/2011
3	Headache (Headaches) 01/2021 - 06/2004
3	Chronic Urticaria 01/2021 - 11/2005
3	Chronic Disease (Chronic Diseases) 12/2020 - 09/2004
3	Hyperplasia 01/2018 - 05/2011
3	Urticaria (Hives) 10/2016 - 09/2002
3	Facial Pain (Myofacial Pain) 01/2012 - 03/2011
2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022 - 07/2005
2	Virus Diseases (Viral Diseases) 03/2021 - 04/2007

Drug/Important Bio-Agent (IBA)

57	Immunoglobulin E (IgE)IBA 01/2022 - 11/2002
34	CytokinesIBA 01/2022 - 01/2005
29	Enterotoxins (Enterotoxin)IBA 12/2020 - 11/2002
27	AllergensIBA 01/2022 - 01/2009
23	Interleukin-5 (Interleukin 5)IBA 11/2022 - 03/2004
21	dupilumabIBA 01/2022 - 12/2015
19	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 09/2002
19	Proteins (Proteins, Gene)FDA Link 08/2021 - 09/2004
18	Biomarkers (Surrogate Marker)IBA 11/2022 - 04/2012
15	AntibodiesIBA 12/2020 - 11/2003
13	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 03/2004
13	Interleukin-13IBA 01/2021 - 01/2008
12	SuperantigensIBA 12/2020 - 05/2002
11	Pharmaceutical PreparationsIBA 01/2022 - 01/2012
10	InterleukinsIBA 11/2022 - 11/2002
9	Omalizumab (Xolair)FDA Link 01/2022 - 01/2009
8	Interleukin-4 (Interleukin 4)IBA 01/2021 - 01/2008
8	Messenger RNA (mRNA)IBA 01/2021 - 06/2005
7	Biological ProductsIBA 01/2022 - 11/2006
7	Nasal SpraysIBA 01/2022 - 09/2002
7	Mometasone Furoate (Nasonex)FDA LinkGeneric 01/2022 - 09/2005
7	Monoclonal AntibodiesIBA 01/2022 - 01/2019
7	Anti-Bacterial Agents (Antibiotics)IBA 08/2019 - 12/2005
7	Eosinophil Cationic ProteinIBA 01/2013 - 06/2005
6	ChemokinesIBA 04/2022 - 01/2005
6	Interleukin-10 (Interleukin 10)IBA 10/2021 - 01/2008
6	SteroidsIBA 01/2020 - 11/2003
6	desloratadine (Aerius)FDA LinkGeneric 01/2012 - 09/2007
6	levocetirizine FDA LinkGeneric 11/2011 - 10/2004
5	mepolizumabIBA 01/2022 - 12/2015
5	azelastine (Optivar)FDA LinkGeneric 12/2020 - 11/2011
5	anti-IgE antibodiesIBA 01/2020 - 01/2009
5	Transforming Growth Factor beta (TGF-beta)IBA 01/2018 - 05/2002
5	Histamine Antagonists (Antihistamines)IBA 04/2015 - 06/2004
4	PeriostinIBA 08/2021 - 12/2015
4	Interleukin-33IBA 01/2021 - 01/2018
4	Fluticasone (Cutivate)FDA LinkGeneric 12/2020 - 05/2012
4	Immunoglobulins (Immunoglobulin)IBA 01/2020 - 02/2008
4	SmokeIBA 01/2020 - 07/2010
4	CollagenIBA 04/2015 - 08/2009
4	Peroxidase (Myeloperoxidase)IBA 01/2013 - 07/2006
4	fexofenadine (Allegra)FDA LinkGeneric 11/2011 - 04/2003
4	LeukotrienesIBA 04/2009 - 06/2005
3	Complement System Proteins (Complement)IBA 01/2022 - 09/2009
3	Matrix Metalloproteinases (MMPs)IBA 08/2021 - 05/2010
3	Toll-Like Receptors (Toll-Like Receptor)IBA 03/2021 - 05/2009
3	Adenosine Triphosphate (ATP)IBA 01/2021 - 12/2019
3	HMGB1 Protein (HMG1)IBA 01/2021 - 12/2019
3	Peptides (Polypeptides)IBA 01/2019 - 04/2010
3	Immunoglobulin G (IgG)IBA 01/2019 - 01/2011
3	TabletsIBA 12/2018 - 11/2014
3	MP29-02IBA 04/2015 - 05/2012
3	GlucocorticoidsIBA 04/2015 - 05/2010
3	Histamine (Histamine Dihydrochloride)FDA Link 11/2011 - 04/2009
3	EicosanoidsIBA 04/2008 - 06/2005
3	Transforming Growth Factor beta1 (TGF beta 1)IBA 02/2008 - 09/2004
2	prostaglandin D2 receptorIBA 01/2022 - 01/2021
2	Tissue Inhibitor of Metalloproteinase-2IBA 08/2021 - 05/2010
2	Extracellular Matrix ProteinsIBA 08/2021 - 01/2013
2	Tissue Inhibitor of Metalloproteinase-3IBA 08/2021 - 05/2010
2	Tissue Inhibitor of Metalloproteinase-1IBA 08/2021 - 05/2010
2	Interleukin-17 (Interleukin 17)IBA 01/2021 - 01/2016

Therapy/Procedure

36	Therapeutics 01/2022 - 09/2005
11	Immunotherapy 01/2021 - 01/2009
10	Drug Therapy (Chemotherapy) 01/2021 - 01/2012
4	Precision Medicine 01/2021 - 01/2017
2	Injections 10/2021 - 01/2014